Schizophrenia is a complex and debilitating illness with strong genetic loading. In line with its heterogeneous symptomatology, evidence suggests genetic etiologies for the phenotypes in schizophrenia. A search across endophenotypes has pointed towards consistent findings in its neurocognitive deficits. Extensive literature has demonstrated impaired cognition including executive function, attention, and memory in schizophrenia patients when compared to healthy subjects. This review (1) provides an overview of recent studies and (2) develops an up-to-date conceptualization of genetic variations influencing neurocognitive functions in schizophrenia patients. Several neurotransmitter system genes have been examined given knowledge of their role in brain functions and their reported genetic associations with schizophrenia and cognition. Several genetic variations have emerged as having preliminary effects on neurocognitive deficits in schizophrenia. These include genes in the neurotrophic, serotonin, cell adhesion, and sodium channel systems. Limited evidence also suggests the dopaminergic system genes, with the most studied catechol-o-methytransferase (COMT) gene showing inconsistent findings. Further investigations with larger samples and replications are required to elucidate genetic risk for cognitive deficits in schizophrenia.
2013; McGrath et al., 2008) . The core features of this disorder are characterized by three symptom domains including positive symptoms, negative symptoms, and cognitive deficits (APA, 2013) . The identification of neurocognitive deficits in schizophrenia patients is important because cognitive impairment is associated with poor functional outcome (Lepage et al., 2014) . Up to 98% of schizophrenia patients have a degree of neurocognitive impairment (Heinrichs and Zakzanis, 1998; Keefe et al., 2005) . Although antipsychotic medications reduce positive symptoms significantly, they have limited efficacy for remediating neurocognitive deficits and negative symptoms of schizophrenia (Carpenter and Koenig, 2008; Keefe and Harvey, 2012) .
Cognitive dysfunction has repeatedly been identified as one of the hallmark features of schizophrenia starting as early as 1950 by Bleuler (1950) and recently in the past decade (Lepage et al., 2014; Heinrichs and Zakzanis, 1998; Green et al., 2000; Barnett et al., 2010) . A systematic review reported global cognitive impairment and specifically worse verbal memory, executive function, and general IQ, in first-episode psychotic patients when compared to healthy controls (Aas et al., 2014) . Recent metaanalyses also detected significant deficits in working memory, attention/vigilance, verbal/visual learning and memory, executive functions (reasoning and problem solving), processing speed, social cognition, and psychomotor control (Keefe and Harvey, 2012; Green et al., 2004) .
Evidence has shown that schizophrenia and cognitive impairment have heritability ranging between 70 and 90% and 24 and 55% respectively (Greenwood et al., 2007; Sabb et al., 2008) . Schizophrenia is a complex and heterogeneous neuropsychiatric disorder with a polygenic architecture (Sullivan et al., 2012) and even following recent genome-wide association studies (GWAS) (Ripke et al., 2013; Biological insights, 2014) , multiple small gene effects with only several replicable findings have been found to contribute to risk. Therefore, the identification of endophenotypes, with an attempt to ascertain a more homogeneous phenotype for genetic studies, is important for elucidating the etiology of schizophrenia. The search for endophenotypes is guided by their strong association with the illness, high heritability, and observable similar deficits in unaffected relatives (Gur et al., 2007) . Cognitive deficits are heritable and are core features of schizophrenia, thus they may be valuable endophenotypes for schizophrenia. Twin studies (Cannon et al., 2000; Pardo et al., 2000; Toulopoulou et al., 2007) and two recent molecular genetic studies Fernandes et al., 2013) have reported significant genetic overlap between neurocognition and schizophrenia. Additionally, neuropsychological studies have observed that unaffected relatives of schizophrenia patients performed significantly worse in estimated intelligence, immediate and delayed logical memory, immediate visual reproduction, and sustained attention, therefore implicating genetic loading within families (Faraone et al., 2000; Agnew-Blais and Seidman, 2013; Hilti et al., 2010) . Although research on the genetics of neurocognitive domains in schizophrenia has grown rapidly over the last decade in parallel with attempts to determine the genetic etiology of schizophrenia, the last review to have covered some genetic studies of cognitive endophenotypes in schizophrenia was published in 2008 (Golimbet, 2008) . Therefore, we now provide an up-to-date review of this important topic.
Methods
We reviewed all molecular genetic studies of cognition in schizophrenia that were published in PubMed and/or MEDLINE until January 1, 2015. Specific search terms used included: genetics, molecular genetics, schizophrenia, cognition, neurocognition, cognitive or neurocognitive or neuropsychological deficits or impairments or endophenotypes or traits. Eighty-two original studies were included in this review article. A summary can be found on Table 1 ( Table S1 in Supplement 1 for full details).
Results
Many genes have been reported to be associated with cognitive impairment in schizophrenia as shown in Table S1 in Supplement 1. The next sections of this review will provide a comprehensive summary of these genetic findings organized according to important bio-molecular systems (Fig. 1 ).
Dopaminergic system genes
The dopaminergic system genes that have been investigated in neurocognitive deficits of schizophrenia include catechol-Omethyltransferase (COMT) (Barnett et al., 2010 (Barnett et al., , 2007 Nicodemus et al., 2013; Cruz et al., 2013; Alfimova et al., 2006 Alfimova et al., , 2013 Bilder et al., 2002; Bosia et al., 2007; Egan et al., 2001; Galderisi et al., 2005a; Goldberg et al., 2003; Golimbet et al., 2006; Joober et al., 2002; Nolan et al., 2004; Rosa et al., 2004; Rybakowski et al., 2006a; Szoke et al., 2006; Greenwood et al., 2011; Cassidy et al., 2014; Swaminathan et al., 2012; Ayoub et al., 2012) , dopamine transporter (DAT) (Barnett et al., 2010; Nicodemus et al., 2013; Rybakowski et al., 2006a; Ayoub et al., 2012; Szekeres et al., 2004) , dopamine D1 receptor (DRD1) (Barnett et al., 2010) , dopamine D2 receptor (DRD2) (Barnett et al., 2010; Alfimova et al., 2013; Cassidy et al., 2014) , dopamine D3 receptor (DRD3) (Barnett et al., 2010; Swaminathan et al., 2012; Szekeres et al., 2004) , dopamine D4 receptor (DRD4) , dopamine D5 receptor (DRD5) , dopamine beta-hydroxylase (DBH) (Green et al., 2004; Swaminathan et al., 2012) , vesicular monoamine transporter 2 (SLC18A2) (Barnett et al., 2010; Swaminathan et al., 2012) , ankyrin repeat and kinase domain containing 1 (ANKK1) (Barnett et al., 2010) , and protein phosphatase 1, regulatory (inhibitor) subunit 1B (PPP1R1B) (Barnett et al., 2010) .
The most extensively examined candidate gene in neurocognition of schizophrenia is COMT. A reduction in dopaminergic neurotransmission in specific brain regions such as the anterior cingulated and the dorso-lateral prefrontal cortex has been postulated to alter cognition, specifically executive function and working memory, in schizophrenia . A functional polymorphism within COMT, Val158Met, accounts for a four-fold variation in its enzymatic activity and dopamine catabolism in the prefrontal cortex, with Met as the low functioning allele (Egan et al., 2001) . Twenty three studies were found as defined by our search criteria (Barnett et al., 2007) . Barnett et al. (2007) performed a meta-analysis including 12 studies of the impact of COMT Val158Met on executive function and detected significant association between Val/Val and worse cognitive performance than Met/Met only in healthy controls but not in schizophrenia patients. A recent study (Alfimova et al., 2013) similarly reported no association between this locus and theory of mind dysfunction in schizophrenia but detected worse performance in Met-carrier females in the combined schizophrenia and control sample. However, a 94-multi-gene family study examining COMT, found associations with verbal learning, 'false' memory, and prepulse inhibition in schizophrenia patients (Greenwood et al., 2011) . Twamley et al. (2014) also reported better learning, memory, and abstraction with the Met allele than Val, and when Green et al. (2014) investigated cognitive function in schizophrenia patients with childhood trauma history, they detected significant links of the Val homozygotes with worse cognitive performance in the absence of childhood adversity, and better executive function with positive abuse history, suggesting a gene-environment interaction. Overall, given the pleiotropic effects of most genes, it appears unlikely that Alfimova et al., 2013 Alfimova et al., , 2006 Barnett et al., 2007; Bosia et al., 2007 Bosia et al., , 2015 Szoke et al., 2006; Rybakowski et al., 2006a; Ho et al., 2005; Galderisi et al., 2005b; Nolan et al., 2004; Rosa et al., 2004; Goldberg et al., 2003; Joober et al., 2002; Bilder et al., 2002; Egan et al., 2001; Green et al., 2014; Greenwood et al., 2011; Twamley et al., 2014; Lopez-Garcia et al., 2013; Kukshal et al., 2013; Zilles et al., 2012; Bombin et al., 2008; Simons and van Winkel, 2013; Kontis et al., 2013 Greenwood et al., 2011; Simons and van Winkel, 2013; Cannon et al., 2005; Hennah et al., 2005; Burdick et al., 2005; Callicott et al., 2005) Simons and van Winkel, 2013; Alfimova et al., 2008a; Ho et al., 2006 Ho et al., , 2007 Rybakowski et al., 2006a; Ahmed et al., 2015; Egan et al., 2003b; Chung et al., 2010; Lu et al., 2012; Zhang et al., 2012) NRG1 2 2 0 2 -Processing speed, visuomotor speed, attention, long-term episodic memory, short-term memory (Greenwood et al., 2011; Simons and van Winkel, 2013; Voineskos et al., 2013; Alfimova et al., 2011 1 . Candidate gene studies according to their biomolecular systems. Dopaminergic system genes have been examined the most in genetic studies of cognition in schizophrenia given the important role of dopamine in the etiology of schizophrenia and cognition. Neurodevelopmental genes are amongst the second most commonly studied candidate, followed by serotonergic and glutamatergic system genes. Although the glutamate hypothesis in schizophrenia has sparked new insight into the mechanism of schizophrenia, only 4% of studies have examined genes related to glutamatergic system. changes in cognition in relation to COMT are specific to schizophrenia.
Other dopamine-related genes, DAT, DRD1, DRD2, DRD3, DRD4, DRD5, DBH, SLC18A2, ANKK1, and PPP1R1B, have also been investigated in cognitive deficits of schizophrenia. These genes were examined because of their prior association with schizophrenia, antipsychotic actions, and/or their involvement in dopamine neurotransmission. Four studies involved DAT, one with rs6350 and three with the functional 3 VNTR, but none reported association with cognitive measures in schizophrenia Rybakowski et al., 2006a; Ayoub et al., 2012; Szekeres et al., 2004) . Three studies investigated DRD2 markers in executive functioning and theory of mind impairment (Alfimova et al., 2013) in schizophrenia (Barnett et al., 2010 ) and all were negative. Two significant and one negative studies of DRD3 have been published. Firstly, Szekeres et al. (2004) reported a significant association between the DRD3 Ser9Gly low functioning (Jeanneteau et al., 2006) Ser/Ser genotype and fewer categories completed and more perseverative errors on the Wisconsin Card Sort Test (WCST) than Ser/Gly. Secondly, a 94-multi-gene study reported a significant association between DRD3 and emotional recognition (Greenwood et al., 2011) . However, Cassidy et al. (2014) only detected significant associations of DRD3 in the combined first-episode psychosis and healthy adolescents suggesting a lack of power. One DRD5 study reported a significant association between the presence of two copies of the 7 (148-bp) allele in the (CT/GT/GA)n microsatellite and lower word generation (visual voluntary attention) than one copy of the 7 allele in schizophrenia (P = 0.018) and their relatives. Swaminathan et al. (2012) reported no association between COMT, DRD3, DBH, and SLC18A2 with performance in the Trail Making Test. For the DBH 19-bp deletion, Green et al. (2004) detected significantly poorer immediate mem-ory with the carriers in schizophrenia patients but not in controls. Several markers across DAT, DRD1, DRD3, and SLC18A2 were also found to be significantly associated with poorer cognitive functions in schizophrenia patients in a multi-gene study (Barnett et al., 2010) .
Thus, dopamine-related genes may be implicated to a limited extent in the neurocognitive deficits in schizophrenia patients, especially in memory, attention and executive function. However, except for COMT, few studies have examined other dopamine-related genes and recent GWAS of cognitive performance in schizophrenia Fernandes et al., 2013; Hargreaves et al., 2013; Dickinson et al., 2014) failed to implicate any dopamine-related genes, suggesting the existence of additional possible mechanisms and interactions in the genetic etiology of neurocognitive deficits in schizophrenia and the need for more systematic studies.
Neurodevelopmental and neuroplasticity genes
Genes related to neurodevelopment and neuroplasticity are obvious candidates for cognitive deficits in schizophrenia.
The dystrobrevin binding proteint 1 (DTNBP1) gene encodes dysbindin, a key subunit of the biogenesis of lysosome-related organelles complex-1, which regulates protein trafficking and cellsurface expression of neurotransmitter receptors (Tang et al., 2009) It has been shown to modulate prefrontal cortical activity via glutamatergic neurotransmission (Talbot et al., 2004; Numakawa et al., 2004) . Significant reduction of DTNBP1 in glutamatergic neuronal terminal fields in the hippocampus has been reported and Talbot et al. (2004) postulated that glutamatergic dysconnectivity may contribute to cognitive impairment in schizophrenia. Four studies examined the effect of this gene in cognitive deficits of schizophrenia. Burdick et al. (2007) first demonstrated an association between a schizophrenia risk haplotype of DTNBP1 (rs909706-rs1018381-rs2619522-rs760761-rs2619528-rs1011313), CTCTAC, and greater decline in IQ in 183 schizophrenia/schizoaffective disorder patients. Baek et al. (2012) later reported a significant association between DTNBP1 rs760761 and rs1018381 and the attention/vigilance domain when comparing schizophrenia patients to controls. Another study (Donohoe et al., 2007a) reported that the DTNBP1 rs2619539-rs3213207-rs2619538 C-A-T haplotype was associated with impaired spatial working memory performance. However, one study (Peters et al., 2008) did not report any association between single tagging sequence variants and their relevant haplotypes across DTNBP1 and neurocognitive endophenotypes in schizophrenia after separating individuals into cognitive deficit and cognitive sparing groups.
The disrupted in schizophrenia 1 (DISC1) gene is considered to be a central hub of cellular development and regulation given its importance in neurogenesis and neuroplasticity (Millar et al., 2000) . It has been previously shown to be associated with schizophrenia, initially from a large multiplex family although not specific to schizophrenia (Blackwood et al., 2001 ) and a recent European meta-analysis (Schumacher et al., 2009 ). Furthermore, the down-stream cascade of DISC1 and its interaction with phosphodiesterase-4B have been implicated in learning, memory, and mood (Millar et al., 2005) . Thus, DISC1 has become a candidate for the genetic study of neurocognitive dysfunctions in schizophrenia (Ishizuka et al., 2006) . Five studies have been reported. The first (Cannon et al., 2005) reported an association between the DISC1/translin-associated factor X (TRAX) haplotype and impairments in short-and long-term memory and reduced gray matter density in the prefrontal cortex. The second reported an association between the DISC1-HEP3 (rs751229-rs3738401) haplotype and poorer performance on short-term visual memory and attention. The third demonstrated a significant finding between DISC1 rs821616 Ser/Ser genotype and reduced performance on WMS Logical Memory II subsection in schizophrenia patients in addition to a lower WCST category scores in the entire sample (schizophrenia, unaffected siblings, parents, and healthy controls) (Callicott et al., 2005) . Burdick et al. (2005) observed positive association between DISC1 rs2255340 genotype and rapid visual search and verbal working memory. The last is a recently published multi-gene study who reported a trend association between DISC1 rs12133766 and deficient verbal fluency in schizophrenia males (P = 0.049).
Neurotrophic factors have been postulated to affect cognition given their roles in neuroplasticity and their interactive and modulatory effects on various neurotransmitter systems. The brain-derived neurotrophic factor (BDNF) gene has been examined due to its role in cell differentiation, survival, long-term potentiation, synaptic plasticity, learning, and memory (Numakawa et al., 2010; Guillin et al., 2001; Cowansage et al., 2010; Lee et al., 2004) . Its functional polymorphism, rs6265 (Val66Met), has been extensively investigated with prior significant associations in memory impairment (Egan et al., 2003a) and schizophrenia (Gratacos et al., 2007) . Eight studies in addition to a multi-gene study and a metaanalysis including seven studies from our search were detected. Egan et al. (2003b) detected a significant association between individuals with one or two Met allele(s) regardless of their disease status (schizophrenia patients, their healthy siblings, and healthy controls) and lower abilities to perform tasks of learning and memory. Another study Alfimova et al. (2008a) reported that schizophrenia patients with the high-functioning Val/Val genotype of BDNF Val66Met had superior scores for both voluntary and involuntary attention tasks, in contrast to the serotonin 2A receptor gene (HTR2A T102C)T-Met combination, linked to inferior performance for voluntary attention but superior performance for involuntary attention. Ho et al. (2006) observed a significant association between the BDNF Met allele with poorer verbal memory performance in both schizophrenia patients and healthy volunteers, and visuospatial impairment in schizophrenia only. Val carriers were found to be associated with better visuospatial and constructional performance in both schizophrenia and healthy subjects whereas only schizophrenic Met carriers had significantly greater attention impairment . In another study, schizophrenic Met carriers showed higher percentage of WCST perseverative errors especially in males . Although Rybakowski et al. (2006b) , Ho et al. (2007) , and Chung et al. (2010) reported no association between BDNF Val66Met and cognitive performance, Ho et al. (2006) (Ahmed et al., 2015) and a recent multi-gene study also did not support a role of BDNF in schizophrenia patients with cognitive deficits .
Although three of the four studies above showed modest significant association between DTNBP1 variants and poor cognitive performance in schizophrenia patients, and five studies suggested some associations of DISC1 genetic variants in neurocognitive deficits in schizophrenia, the recent GWAS (Fernandes et al., 2013) support neither of these genes as being strongly related to schizophrenia. Furthermore, a recent meta-analysis did not support the involvement of BDNF Val66Met in psychotic patients with neurocognitive deficits. Thus, the overall status of these genes in neurocognitive function in schizophrenia remains unresolved.
Glutamatergic system genes
The glutamatergic neurotransmitter system has received much attention given its neuronal excitatory properties in network functions throughout the brain, especially in the cerebral cortex, its influence in psychotic and cognitive symptoms, as well as being a source of potential drug targets (Falkenberg et al., 2014; Egerton and Stone, 2012) . In animal studies, the mGluR3 knockout mouse showed hyperactivity and impaired working memory (Amann et al., 2010; Fujioka et al., 2014) , and these cognitive deficits are consistent with those of schizophrenia patients (Keefe and Harvey, 2012; Aas et al., 2014) . Reduction in glutamate levels has also been found in schizophrenia patients with impaired cognitive control functioning but not in healthy controls (Falkenberg et al., 2014) .
Effects of glutamatergic modulatory drugs such as mGluR2/3 agonists (i.e. metabotropic glutamate receptor group II agonists), have been investigated in animal models of schizophrenia (Schlumberger et al., 2009; Woolley et al., 2008) . Other drugs that regulate activation or inhibition of the N-methyl-d-aspartate (NMDA) receptor including the glycine transporter-1 inhibitors (Hashimoto et al., 2013) and NMDA receptor antagonist (Meltzer et al., 2013) have also been investigated for their potential role in the treatment of cognitive impairment in schizophrenia. These medications have had mixed results in early clinical trials in schizophrenia but more recently, a mGluR2/3 agonist has shown promising results in the treatment of early psychosis (Kinon and Gomez, 2013) , possibly with relatively good efficacy for cognition, in particular, working memory (Coyle and Tsai, 2004) .
Of the glutamatergic system genes, only three have been studied: the glutamate receptor, ionotropic, N-methyl-d-aspartate, subunit 2B (GRIN2B) Jablensky et al., 2011) , GRIN2A (Jablensky et al., 2011) , and glutamate receptor, metabotropic 3 (GRM3) (Jablensky et al., 2011) . Jablensky et al. (2011) reported a significant association between the GRIN2B rs220599T allele with poorer immediate and delayed recall on the Rey Auditory Verbal Learning Test; however, Nicodemus et al. (2013) did not detect any positive findings with this gene in cognitive deficits of schizophrenia. Jablensky et al. (2011) also observed enhanced cognitive performance with the GRM3 rs2189814C allele but not with GRIN2A.
Very few studies of glutamate system genes have examined neurocognitive impairments in schizophrenia, although new medications targeting the glutamatergic system have shown possibly promising results in the treatment of cognitive deficits in schizophrenia and in reducing psychosis. The use of genetic tools to subdivide groups of patients in trials of new glutamatergic drugs may help to identify patients, whose cognition will show greater improvement, thus pointing to more personalized treatment options.
Serotonergic system genes
The serotonergic system interacts with many neurotransmitter systems and serotonin plays an important role in the regulation of morphogenesis in CNS development, neuronal proliferation, migration, differentiation, and cognition (Vitalis and Parnavelas, 2003; Schmitt et al., 2006; Arnsten, 2004) . In term of gene expression, the frontal cortex and anterior cingulate cortex have approximately 10-fold higher mRNA expression of the serotonin 2A receptor (HTR2A) than hippocampus or caudate and putamen according to the Genetic Tissue Expression database (GTEx: http://www. gtexportal.org).
Five studies have examined the HTR2A T102C polymorphism Alfimova et al., 2008a Alfimova et al., , 2003 Chen et al., 2001; Ucok et al., 2007) with three significant associations. As mentioned above, Alfimova et al. (2008b) reported a significant association between the T allele and more time for performing the test in addition to the T-(BDNF Val66Met)Met combination and lower scores for voluntary attention and higher scores for involuntary attention. Ucok et al. (2007) reported significant associations between the high expression (Polesskaya and Sokolov, 2002) T allele with a lower hit rate in Continuous Performance Task (CPT) and the T/C genotype with more commission errors on CPT and fewer correct responses on WCST. Alfimova et al. (2003) reported a significant association between the T/T homozygotes and lower verbal fluency in male schizophrenia patients only and not the entire sample, including controls. Although Chen et al. (2001) did not detect a significant association between the HTR2A T102C polymorphism and cognitive deficits in schizophrenia patients. The authors observed a trend between T/C genotype and better verbal fluency and less motor co-ordination soft neurological signs. Nicodemus et al. (2013) however did not demonstrate any role of this genetic variation in cognitive deficits in schizophrenia.
Besides HTR2A, one study of the serotonin 1A receptor (HTR1A) (Bosia et al., 2011) and three studies of the serotonin transporter (5HTT, also known as SLC6A4) (Bosia et al., 2010) have been conducted. Bosia et al. (2011) reported schizophrenia patients with the low-expression (Lemonde et al., 2003) CC genotype of HTR1A −1019C/G polymorphism performed better on Theory of Mind tasks. Bosia et al. (2010) reported a significant association between the HTTLPR polymorphism and executive function and sustained attention, specifically the high activity long allele with better executive performance and with poorer attention, but two additional studies were negative Ayoub et al., 2012) .
Genome-wide association studies (GWAS)
To date, five GWAS have been published recently (see Table  S1 in Supplement 1 for full details). The first GWAS was published in 2012 and written in Chinese (Xiang et al., 2012) . Xiang et al. (2012) identified five risk genes, which were associated with memory deficits. The second GWAS examining genetic influence of neurocognitive traits in schizophrenia found the strongest genetic enrichments for performance in a colour-interference Stroop test and sets associated with the rate of learning (Fernandes et al., 2013) . The third GWAS reported significant genetic overlap between general cognitive ability and risk for schizophrenia, implicating similar pathophysiological processes between the two. Although schizophrenia patients had lower general cognitive ability than healthy controls, the authors did not detect genome-wide significance. In the meta-analysis , they observed significant association between MAD1 mitotic arrest deficient-like 1 (MAD1L1) and cyclin M2 (CNNM2) and lower general cognitive ability. Additionally, the LSM1 homologue, U6 small nuclear RNA associated (LSM1) and the neurogranin (protein kinase C substrate, RC3) (NRGN) schizophrenia risk alleles were associated with higher cognitive ability in schizophrenia patients . Through the recent PGC schizophrenia GWAS, Hargreaves et al. (2013) detected an increased polygenic risk score for the cell adhesion molecule pathway with poorer performance on memory and attentional tasks. The strongest signal was detected within the human leukocyte antigen system, HLA-DQA1 rs9272105 marker, which was associated with attentional control only. The latest GWAS (Dickinson et al., 2014) showed genome-wide significant associations between cognitive ability in schizophrenia and polymorphisms in the sodium channel, voltage-gated, type II, alpha subunit (SCN2A) gene.
Genetics of normal cognition, Alzheimer's disease, and other cognitive disorders
General intelligence may in fact play a role in cognitive deficits of schizophrenia patients. Therefore, we included a brief summary of the genetics of general intelligence in healthy individuals and patients with cognitive disorders in order to determine whether there are distinct genetic risks that differentiate between healthy individuals, patients with cognitive disorders, and schizophrenia patients with cognitive deficits.
A GWAS of general intelligence has not yielded genome-wide significance in 3511 healthy adults (Davies et al., 2011) ; however, using a gene-based approach, Davies et al. (Davies et al., 2011) detected a genome-wide significant association with the formingbinding protein 1-like (FNBP1L) gene but it was not replicated in an independent sample from the same study. The apolipoprotein E (APOE) gene was found to be associated with cognition in older individuals, suggesting a genetic overlap with Alzheimer's disease (Shi et al., 2014) . A recent review article on GWAS in Alzheimer's disease identified several major pathways, including amyloid, immune system, inflammation, lipid transport and metabolism, synaptic functioning, and endocytosis (Tosto and Reitz, 2013) . Similarly in a recent review of the genetics of recessive cognitive disorders, significant associations have been found in genes that are involved in synaptic function, basic cellular processes including DNA transcription, translation, and degradation, mRNA splicing, energy metabolism, and fatty-acid synthesis and turnover (Najmabadi et al., 2011; Musante and Ropers, 2014) .
There are genetic overlaps between general intelligence in healthy individuals, cognitive disorders, and cognitive deficits in schizophrenia (Table 2 ) . Interestingly, energy metabolism appears to be a common genetic pathway that affects cognition regardless of disease status. Nonetheless, many genes have been detected in specific disorders but replication studies are required to further expand on these reports and to differentiate disease-specific genetic markers.
Treatment implications
Pharmacotherapy of schizophrenia has only shed light in the treatment of positive, but not cognitive or negative symptoms. No known treatment has provided significant improvement in these latter symptoms to date. Since cognitive and negative symptoms are associated with poor functional outcome, the development of new pharmacological strategies is crucial for reducing disease-related disability. Recent studies of cognitive enhancers and immunomodulatory drugs have reported promising effects on cognition in schizophrenia (Koola et al., 2014; Kroken et al., 2014) ; however, replications are warranted to provide support for clinical application. Thus, the search for genetic vulnerability in cognition and eventual discovery of a biomarker will enable researchers to identify new drug targets, which will hopefully lead to the improvement of cognitive deficits in schizophrenia patients.
Discussion
This is the first comprehensive attempt to review all molecular genetic studies of cognitive impairments in schizophrenia to date. Neurocognitive deficits are one of the key symptom dimensions of schizophrenia. The study of cognition in schizophrenia is a strong and important unmet need for new drug targets since cognitive deficits are often the most difficult to treat.
Although 82 publications were qualified according to our search criteria, a considerable expansion of current work will be required to further identify risk loci for cognitive dysfunction in schizophrenia. Multiple genetic variants have been examined in different cognitive domains in schizophrenia but there have been few replication studies to date. The most examined candidate genes include COMT, DISC1, HTR2A, and BDNF, which all provided inconsistent findings, often associated with different aspects of cognitive dysfunction in schizophrenia.
Evidence has suggested overlapping genetic etiology between neurocognition and schizophrenia (Toulopoulou et al., 2007) .
Although the number of molecular genetic studies is growing, these studies use traditional clinical and convenient neuropsychological test measures, which are often insensitive, non-specific, and neurally ill-defined. The hope is for a more homogeneous phenotype; however, current studies often use the label of cognitive impairment loosely in schizophrenia. Many of these studies focused on genes that were previously implicated in schizophrenia and very few of them have investigated interactions between genetic variations across different genes. Calcium and sodium channels have emerged in recent schizophrenia genetic association studies as well as the most recent GWAS examining cognitive impairment in schizophrenia. These will hopefully lead researchers to search for an underlying common mechanism that may partly explain the etiology of schizophrenia and its related cognitive deficits. Advances in bioinformatics are allowing researchers to analyze large datasets despite the relatively low prevalence of schizophrenia and multiple common loci explaining only small fractions of the genetic variance. Linking functional implication to identified genetic markers (e.g., expression via GTEx) and testing these functional hypotheses may prove to advance our understanding of the etiology of neurocognitive dysfunction in schizophrenia.
The complexities of both schizophrenia and cognition provide additional challenges including the potential role of illness epiphenomena and illness-specific mechanisms of cognitive impairment. Furthermore, one of the two twin studies that have examined the genetic influences in schizophrenia and cognition detected limited genetic overlap between the two (Fowler et al., 2012) . Suggestive of the lack of overlap can be observed in two schizophrenia risk alleles counter-intuitively being associated with better cognitive performance . Common genetic markers affecting cognitive performance in schizophrenia may not have been detected at present given the complex interactions of genetic, environmental, and random influences that affect individuals across their developmental stages and lifespan. Investigating interactions between other endophenotypes of schizophrenia that may be related to cognitive functions, such as neuroimaging findings, are potentially crucial for linking genetics to brain structure and function. Larger sample sizes with definition of homogeneous subgroups may aid in the identification of specific and shared genetic markers that influence schizophrenia and cognition. Moreover, there are numerous different facets of neurocognition and many different methods for testing these cognitive domains; thus, development of a broad battery of systematic and well-standardized cognitive tasks that are reliable, easy to interpret, and comparable based on modern cognitive neuroscience approaches will be required in order to derive more definitive conclusions. Significant associations with performance on a single test of a particular function such as working memory or attention will ideally be supported by more than one test measure. The behavioural specificity of such effects will also need to be carefully assessed. One major, though controversial, hypothesis relating to intellectual deficits in schizophrenia is that it may be driven by the general factor, g, from conventional IQ tests (Barnett et al., 2006; Leeson et al., 2011) . The relationship of specific, or general, aspects of cognition to identified neural system dysfunction is also required so that neurocognitive phenotypes and endophenotypes can be accurately delineated.
Further research is warranted to target known hypotheses and mechanisms of cognitive deficits in schizophrenia, which may in turn contribute to the development of preventative measures and new drug targets. Cognitive deficits in schizophrenia are associated with poor functional outcome and therefore, the identification of biomarkers to predict different outcomes may influence treatment options including the intensity, duration, choice of medication, and type of therapy such as brain stimulation. Genetic markers related to electrophysiology and/or neuroplasticity such as BDNF may attract interest and attention in treatment utiliz- Alfimova et al., 2013 Alfimova et al., , 2006 Barnett et al., 2007; Bosia et al., 2007 Bosia et al., , 2015 Szoke et al., 2006; Rybakowski et al., 2006a; Ho et al., 2005; Galderisi et al., 2005b; Nolan et al., 2004; Rosa et al., 2004; Goldberg et al., 2003; Joober et al., 2002; Bilder et al., 2002; Egan et al., 2001; Green et al., 2014; Greenwood et al., 2011; Twamley et al., 2014; Lopez-Garcia et al., 2013; Kukshal et al., 2013; Bombin et al., 2008; Simons and van Winkel, 2013; Kontis et al., 2013; Sagud et al., 2010; Raz and Lustig, 2014; Savitz et al., 2006 ) DAT/SLC6A3 +/− +/− +/− j +/− -Speed of information processing, attention/vigilance, verbal learning and memory, working memory, reasoning and problem solving, set shifting, and verbal comprehension Rybakowski et al., 2006a; Simons and van Winkel, 2013; Szekeres et al., 2004; Lin et al., 2012; Zheng et al., 2012; Colzato et al., 2010) DRD1 + − j -Speed of information processing, attention/vigilance, verbal learning and memory, working memory, reasoning and problem solving, set shifting, and verbal comprehension (Simons and van Winkel, 2013 ) Alfimova et al., 2013; Bombin et al., 2008; Simons and van Winkel, 2013; Savitz et al., 2006; Liu et al., 2014; Small et al., 1997; Colzato et al., 2013; Rodriguez-Jimenez et al., 2006 )
-Speed of information processing, attention/vigilance, verbal learning and memory, working memory, reasoning and problem solving, set shifting, and verbal comprehension (Kukshal et al., 2013; Bombin et al., 2008; Simons and van Winkel, 2013; Szekeres et al., 2004) DRD4 + +/− + +/− Working memory, verbal fluency Lin et al., 2012; Savitz et al., 2006 
Visual voluntary attention ) DBH +/− +/− -+ Immediate memory (Kukshal et al., 2013; Hui et al., 2013; Combarros et al., 2010; Dai et al., 2014) Greenwood et al., 2011; Simons and van Winkel, 2013; Cannon et al., 2005; Hennah et al., 2005; Burdick et al., 2005; Callicott et al., 2005) 
Attention/vigilance domain, spatial working memory, IQ (Simons and van Winkel, 2013; Baek et al., 2012; Peters et al., 2008; Donohoe et al., 2007a; Burdick et al., 2007) Simons and van Winkel, 2013; Alfimova et al., 2008a; Ho et al., 2006 Ho et al., , 2007 Rybakowski et al., 2006a; Ahmed et al., 2015; Egan et al., 2003b; Chung et al., 2010; Lu et al., 2012; Zhang et al., 2012; Savitz et al., 2006) NRG1
Processing speed, visuomotor speed, attention, long-term episodic memory, short-term memory (Greenwood et al., 2011; Simons and van Winkel, 2013; Voineskos et al., 2013; Alfimova et al., 2011) NRG3 + +/− + Visuomotor speed, processing speed, mental flexibililty, executive function, sustained attention (Meier et al., 2013; Morar et al., 2011; Wang et al., 2014) NRN1 Greenwood et al., 2011; Simons and van Winkel, 2013; Alfimova et al., 2008a Alfimova et al., , 2003 Ucok et al., 2007; Chen et al., 2001; Sagud et al., 2010 Hori et al., 2012; Liu et al., 2014; Small et al., 1997 
Cognitive ability (g) (Dickinson et al., 2014; Colzato et al., 2013) (Simons and van Winkel, 2013; Kontis et al., 2013; Yeh et al., 2012; de Lau et al., 2010; Ravaglia et al., 2004; Schiepers et al., 2011; Visscher et al., 2003 "+" indicates previous significant association(s), "-" indicates prior negative association(s), and "+/−" indicates previous positive and negative associations. i This study with two independent samples found significant associations between NOS1 and cognitive function in Irish controls but not in Irish schizophrenia patients, and German schizophrenia patients but not controls. a The list of genes in this table has been cross-referenced with the genetic databases in schizophrenia www.alzgene.org (100) and Alzheimer's disease www.szgene.org (101) and updated with references from PubMed for schizophrenia risk genes, dementia risk genes, and genes affecting normal cognition.
b This study reported a significant association between SNP(s) across this gene and cognitive function(s) in the combined psychosis and healthy control sample. c This study detected a significant association between SNP(s) across this gene only in schizophrenia patients and their unaffected relatives but not in healthy controls. d This study found significant association between SNP(s) across this gene only in schizophrenia patients but not in healthy controls. e This study found significant association between this gene and psychosis in patients with Alzheimer's disease. f This study reported significant associations for MAG in schizophrenia patients and healthy controls but in different cognitive domains and for OLIG2 and ERBB4 in only healthy controls; QKI and CNP were not significant in either sample.
g This study found significant association between DAOA and cognitive function regardless of disease status (psychosis patients and healthy controls). h This study found significant association between TCF4 and cognitive function in schizophrenia patients and healthy controls but opposite alleles associated with cognitive better performance. j This study found significant association between SNP(s) across this gene only in schizophrenia patients but not in their unaffected relatives or healthy controls. ing brain stimulation techniques. New advances in differentiating cognitive deficits, impairment in social cognition, and negative symptoms of schizophrenia, including motivational and emotional measures, may further delineate different subgroups within the current schizophrenia population. Genetic biomarkers may aid in the identification of these subgroups, which may in turn translate into clinical utility via precision medicine.
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